PSC
CBAY

Piper Sandler & Co’s Cymabay Therapeutics CBAY Stock Holding History

Piper Sandler & Co’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-800
Closed -$7K – 18
2017
Q4 		$7K Buy
+800
New +$6.84K 0.01% 12

Other funds holding CBAY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

Piper Sandler & Co's CBAY Position: Q1 2018 in Review

Piper Sandler & Co sold out of Cymabay Therapeutics (CBAY) in Q1 2018, closing a stake of 800 shares — an estimated $7K sold.

Piper Sandler & Co first reported a position in CBAY in Q4 2017 and held it in 1 quarter. The position peaked at $7K in Q4 2017. 107 funds tracked by Wall St. Rank hold CBAY as of Q1 2018.

  • Piper Sandler & Co reported no remaining Cymabay Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Piper Sandler & Co sold 800 Cymabay Therapeutics shares in Q1 2018, an estimated $7K.
  • Piper Sandler & Co first reported a position in Cymabay Therapeutics in Q4 2017 and held it in 1 quarter.
  • Piper Sandler & Co's Cymabay Therapeutics position peaked at $7K in Q4 2017.
  • 107 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q1 2018.

Based on Piper Sandler & Co's 13F filing for Q1 2018, filed 15 May 2018.